^
Association details:
Biomarker:No biomarker
Cancer:Merkel Cell Carcinoma
Drug:Keytruda (pembrolizumab) (PD1 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A1 - Approval
Source:
Published date:
06/29/2020
Excerpt:
KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated...for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma.
Evidence Level:
Sensitive: A2 - Guideline
Source:
Published date:
10/02/2019
Excerpt:
NCCN Recommendations for Selection of Systemic Therapy for Distant Metastatic Disease…3 checkpoint immunotherapies (avelumab, pembrolizumab, and nivolumab) recommended by NCCN as options for metastatic MCC…